Notable earnings before Thursday’s open: ABC, AET, AMLN, AUO, AZN, BC, BG, BLLL, BMY, BWA, CAM, CCE, CELG, CL, CMS, CNX, D, DB, DDD, DNKN, DOW, ELN, EQT, ETR, FIS, GR, GTI, HOT, HP, INCY, IPG, IRM, IVZ, JBLU, K, LINE, LIZ, LLL, LMT, MCO, MJN, MO, MWW, MYL, NBL, NIHD, OCR, ORI, OXY, PCS ,PDS, PEP, PHM, POT, PTEN, RTN, SHPGY, SWC, SWI, SWY, TLAB, TS, TSM, TWC, TYC, UAL, UPS, VNTV, WHR, WM, XEL, XOM, YNDX, ZMH Post your comment!
Originally posted here: Notable earnings before Thursday’s open: [[ABC]], [[AET]], [[AMLN]], [[AUO]], [[AZN]], [[BC]], [[BG]], [[BLLL]], [[BMY]], [[BWA]], [[CAM]], [[CCE]], [[CELG]], [[CL]], [[CMS]], [[CNX]], [[D]], [[DB]], [[DDD]], [[DNKN]], [[DOW]], [[ELN]], [[EQT]],…
NEW YORK (TheStreet) — Watson Pharmaceuticals has bought Actavis for roughly $5.6 billion, paying $1 billion less for the Swiss generic drug maker than initial M&A rumors had suggested.
The merger will make Watson Pharmaceuticals the world’s third largest generics drugs maker with a combined revenue of $8 billion, while increasing its international presence. In unveiling the deal, Watson also said that a combination of synergies and growth opportunities will make the merger additive to earnings in coming years.
“Actavis dramatically enhances our commercial position on a global basis and brings complementary products and capabilities in the United States,” said Watson Pharmaceuticals CEO Paul M. Bisaro, in a statement. “In a single, commercially compelling transaction, we more than double Watson’s international access and strengthen our commercial position in key established European markets as well as exciting emerging growth markets, including Central and Eastern Europe and Russia.”
Click to view a price quote on WPI.
Click to research the Drugs
More: Watson Pharma Gets Actavis at ‘Generics’ Price
Mylan (MYL -2.1%) sues the FDA seeking relief over the 180-day exclusivity granted by the agency to Teva Pharmaceuticals (TEVA +0.4%) over its generic Provigil. Attorneys repping the firm filed the suit at double-speed with the launch of the narcolepsy-fighting drug just crossing the wires less than a week ago. Post your comment!
Read this article: Mylan ([[MYL]] -2.1%) sues the FDA seeking relief over the 180-day exclusivity granted by the agency to Teva Pharmaceuticals ([[TEVA]] +0.4%) over its generic Provigil. Attorneys repping the firm filed the suit at double-speed with the launch of the…
NEW YORK (TheStreet) — Gannett and Mosaic were among the best-performing stocks in the S&P 500 on Wednesday.
Both stocks are rated buy at TheStreet Ratings.
Gannett and Mosaic are among the best-performers of the S&P 500 midday Wednesday.
The S&P 500 fell 4.55 points, or 0.33%, to 1,357.66 on Wednesday.
Click to view a price quote on MOS.
Click to research the Chemicals
Read the original: Gannett, Mosaic: S&P 500 Gainers